The statistically significant responder analysis results for Mytesi® (crofelemer) in the OnTarget study's prespecified subgroup of ...

Jaguar Health (JAGX) announced that Jaguar’s president and CEO Lisa Conte, three other members of the Company’s board of directors, and seven ...

Reverse split approved at March 2025 Special Meeting of Stockholders Shares of Jaguar Health common stock to begin trading on ...

published data from clinical investigations in MVID and SBS-IF could support reimbursed early patient access to crofelemer for these debilitating conditions," Lisa Conte, Jaguar's president and ...

oral plant-based prescription medicine - available to this patient population for cancer therapy-related diarrhea (CTD)," said Lisa Conte, Jaguar's president and CEO. "In this responder analysis ...

provide Jaguar with the opportunity to achieve a share price and outstanding share count that is more attractive to institutional investors," said Lisa Conte, Jaguar's president and CEO.